Holen Sie sich die Stockscreener-App
187.35
1.06%
1.96
Handel nachbörslich:
187.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$185.39
Offen:
$185.56
24-Stunden-Volumen:
1.03M
Relative Volume:
1.10
Marktkapitalisierung:
$20.95B
Einnahmen:
$10.52B
Nettoeinkommen (Verlust:
$999.00M
KGV:
22.40
EPS:
8.3628
Netto-Cashflow:
$1.22B
1W Leistung:
+3.57%
1M Leistung:
+3.73%
6M Leistung:
+12.03%
1J Leistung:
+25.44%
1-Tages-Spanne:
$185.19
$188.11
1-Wochen-Bereich:
$180.98
$188.11
52-Wochen-Spanne:
$146.91
$191.49
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Vergleichen Sie DGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
187.35 | 20.73B | 10.52B | 999.00M | 1.22B | 8.3628 |
|
TMO
Thermo Fisher Scientific Inc
|
527.87 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
206.10 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
639.15 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
139.65 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.12 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
How supply chain issues affect Quest Diagnostics Incorporated stock2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
Is Quest Diagnostics Incorporated stock cheap compared to fundamentalsMarket Volume Summary & High Conviction Buy Zone Picks - newser.com
Is Quest Diagnostics Incorporated trending in predictive chart modelsQuarterly Profit Review & High Accuracy Buy Signal Tips - newser.com
Exit strategy if you’re trapped in Quest Diagnostics IncorporatedJuly 2025 Catalysts & Reliable Entry Point Trade Alerts - newser.com
Is Quest Diagnostics Incorporated (QDI) stock a top pick for value investorsLayoff News & Scalable Portfolio Growth Methods - newser.com
Trend analysis for Quest Diagnostics Incorporated this weekGap Down & Comprehensive Market Scan Reports - newser.com
Will Quest Diagnostics (DGX) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - TradingView
Ranking Quest Diagnostics Incorporated among high performing stocks via toolsTreasury Yields & Daily Market Momentum Tracking - newser.com
Published on: 2025-10-13 22:37:30 - newser.com
Quest Diagnostics (DGX): Evaluating Valuation as Analyst Optimism Builds Ahead of Upcoming Q3 Results - Yahoo Finance
Published on: 2025-10-13 08:58:36 - newser.com
How to read the order book for Quest Diagnostics IncorporatedWeekly Trend Recap & Verified Stock Trade Ideas - newser.com
Quest Diagnostics (DGX) Stock Analysis: Unveiling a 3.05% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
How Quest Diagnostics Incorporated (QDI) stock reacts to stronger dollar2025 Technical Patterns & Stepwise Entry/Exit Trade Alerts - newser.com
What To Expect From Quest Diagnostics’ Next Quarterly Earnings Report - Barchart.com
Published on: 2025-10-12 22:32:22 - newser.com
Sivik Global Healthcare LLC Invests $4.49 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Experiences Revision in Stock Evaluation Amidst Market Dynamics - Markets Mojo
Blair William & Co. IL Buys 38,588 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Sold by Galvin Gaustad & Stein LLC - MarketBeat
Q3 EPS Estimate for Quest Diagnostics Decreased by Analyst - MarketBeat
Rice Partnership LLC Invests $3.33 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Game Plan Financial Advisors LLC Cuts Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Can Quest Diagnostics Incorporated stock sustain breakout momentumSwing Trade & Free Weekly Watchlist of Top Performers - newser.com
Vontobel Holding Ltd. Boosts Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
How Quest Diagnostics Incorporated (QDI) stock responds to job market shifts2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Can Quest Diagnostics Incorporated (QDI) stock retain market dominanceMarket Sentiment Report & Technical Pattern Alert System - newser.com
Quest Diagnostics' (DGX) Buy (B) Rating Reiterated at Weiss Ratings - MarketBeat
Will Quest Diagnostics Incorporated stock hit analyst forecastsJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
What macro factors could drive Quest Diagnostics Incorporated stock higher2025 Key Lessons & Safe Investment Capital Preservation Plans - newser.com
Bar Harbor Wealth Management Invests $2.73 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Janney Montgomery Scott LLC Has $3.62 Million Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Evercore ISI Group Raises Price Target for Quest Diagnostics (DG - GuruFocus
Quest Diagnostics (NYSE:DGX) Price Target Raised to $190.00 - MarketBeat
Evercore ISI Adjusts Price Target on Quest Diagnostics to $190 From $185, Maintains In Line Rating - MarketScreener
Leerink Partners Adjusts Price Target on Quest Diagnostics to $203 From $192, Maintains Outperform Rating - MarketScreener
2,014 Shares in Quest Diagnostics Incorporated $DGX Purchased by Gratus Wealth Advisors LLC - MarketBeat
Appleton Partners Inc. MA Boosts Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Knights of Columbus Asset Advisors LLC Purchases 2,526 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
OLD National Bancorp IN Raises Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Why Quest Diagnostics Incorporated stock could rally stronglyJuly 2025 Outlook & Technical Pattern Alert System - newser.com
Will Quest Diagnostics Incorporated continue its uptrend2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Quest Diagnostics Incorporated stock daily chart insightsJuly 2025 Market Mood & AI Driven Stock Price Forecasts - newser.com
Quest Diagnostics: Investing In Healthcare's Future Today (NYSE:DGX) - Seeking Alpha
How Quest Diagnostics Incorporated (QDI) stock behaves in tightening cycles2025 Trading Recap & Precise Trade Entry Recommendations - newser.com
Evaluating Quest Diagnostics Incorporated with trendline analysis2025 Price Momentum & Smart Money Movement Tracker - newser.com
Technical analysis overview for Quest Diagnostics Incorporated stockTrade Risk Report & Community Consensus Stock Picks - newser.com
What to expect from Quest Diagnostics Incorporated in the next 30 daysWeekly Profit Recap & Verified High Yield Trade Plans - newser.com
74,250 Shares in Quest Diagnostics Incorporated $DGX Bought by Boston Common Asset Management LLC - MarketBeat
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):